Shots:

• Under the terms of an agreement, Regio gets an exclusive license for further development of REG-101 (MEDI5884) to address patients with unmet medical needs including PAD and cardiovascular disease & will lead the research, development, and commercial activities of REG-101
• Additionally, the company is expected to initiate a P-IIa clinical program of REG-101 for the treatment of PAD in H2’22
• REG-101 is designed to reduce the size of cholesterol-rich plaque within peripheral arteries & will directly address the pathophysiology of PAD. Regio has a partnership with CPC and multiple clinical sites in the US to conduct a P-IIa in patients with PAD

Ref: Businesswire | Image: Regio